Treatment of membranous nephropathy with crescent nephritis by rituximab : A case report
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc..
BACKGROUND: Crescent formation is rare in primary membranous nephropathy (MN). The mechanism of crescent formation is unknown and the treatments are tentative.
PATIENT CONCERNS: A 71-year-old woman presented with nephrotic syndrome, hematuria, and rapidly progressive kidney dysfunction.
DIAGNOSIS: Kidney biopsy was performed, and the diagnosis was MN in combination with crescentic glomerulonephritis. Circulating anti-PLA2R was detected of a high level.
INTERVENTIONS: The patient received rituximab besides corticosteroids.
OUTCOMES: The patient achieved complete remission of proteinuria and recovery of kidney function.
CONCLUSION: Our case suggests that there is a pathologic feature of MN and crescents in the absence of known immunologic factors as well as rituximab could serve as an effective cure and could be considered in serious MN conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Medicine - 101(2022), 37 vom: 16. Sept., Seite e30663 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Fan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 22.09.2022 Date Revised 08.11.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000030663 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346404118 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346404118 | ||
| 003 | DE-627 | ||
| 005 | 20231226031350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000030663 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346404118 | ||
| 035 | |a (NLM)36123923 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Fan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of membranous nephropathy with crescent nephritis by rituximab |b A case report |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2022 | ||
| 500 | |a Date Revised 08.11.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a BACKGROUND: Crescent formation is rare in primary membranous nephropathy (MN). The mechanism of crescent formation is unknown and the treatments are tentative | ||
| 520 | |a PATIENT CONCERNS: A 71-year-old woman presented with nephrotic syndrome, hematuria, and rapidly progressive kidney dysfunction | ||
| 520 | |a DIAGNOSIS: Kidney biopsy was performed, and the diagnosis was MN in combination with crescentic glomerulonephritis. Circulating anti-PLA2R was detected of a high level | ||
| 520 | |a INTERVENTIONS: The patient received rituximab besides corticosteroids | ||
| 520 | |a OUTCOMES: The patient achieved complete remission of proteinuria and recovery of kidney function | ||
| 520 | |a CONCLUSION: Our case suggests that there is a pathologic feature of MN and crescents in the absence of known immunologic factors as well as rituximab could serve as an effective cure and could be considered in serious MN conditions | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Yang, Yiya |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yinyin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Yumei |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Xun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 101(2022), 37 vom: 16. Sept., Seite e30663 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2022 |g number:37 |g day:16 |g month:09 |g pages:e30663 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000030663 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2022 |e 37 |b 16 |c 09 |h e30663 | ||